Thickness and level of invasion are the main morphological elements for an approximate but not sufficiently sensitive prognostic evaluation of cutaneous melanomas. By using immunohistochemical methods it is possible to detect biological markers related to prognosis. We have studied p53, PCNA, Bcl-2 and P-gp expression in 49 primary cutaneous melanomas.
Materials
We used the immunophosphatase APAAP immunohistochemical method. The percentage of labeled cells (according to four classes of positivity: <5%; 5-25%; 25-50%; >50%) and the localization of immunoreactivity were expressed for each marker. Statistical analysis was performed to determine the correlations between markers and level or thickness of melanomas.
Results
We found a good correlation between p53 expression and melanoma thickness (P <0.005), PCNA and P-gp expression. No relationship was observed between Bcl-2 expression and the different variables considered or other markers.
Conclusions
Our data seem to indicate an unfavorable prognostic role of higher nuclear p53 expression. However, we believe that our results need to be integrated with patients’ clinical follow-up and with the study of the expression of these markers in benign melanocytic lesions to gain more accurate information about their prognostic significance.
McNuttN.S., Saenz-SantamariaC., VolkenadtM., SheaC.R., AlbinoA.P.: Abnormalities of p53 protein expression in cutaneous disorders.Arch Dermatol,130: 225–232, 1994.
2.
Saenz-SantamariaM.C., McNuttN.S., BogdanyJ.K., SheaC.R.: p53 expression is rare in cutaneous melanomas.Am J Der-matopafhol,17: 344–349, 1995.
3.
WeissJ., HeineM., KornerB., PilchH., JungE.G.: Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications.Br J Dermatol,133: 23–31, 1995.
4.
RoY.S., CooperP.N., LeeJ.A., QuinnA.G., HarrisonD., LaneD., HomeC.H.W., ReesJ.L., AngusB.: p53 protein expression in benign and malignant skin tumours.Br J Dermatol, 128237–241, 1993.
5.
BravoR., FrankR., BlundellP.A., MacDonald-BravoH.: Cy-clin/PCNA is the auxiliary protein of DNA polymerase-d.Nature,326: 515–517, 1987.
6.
FurukawaF., ImamuraS., FujitaM., KinoshitaK., YoshitakeK., BrownW.R., NorrisD.A.: Immunohistochemical localization of proliferating cell nuclear antigen/cyclin in human skin.Arch Dermatol Res,284: 86–91, 1992.
7.
RiegerE., Hoffmann-WellenhofR., SoyerH.P., KoflerR., CerroniL., SmolleJ., KerlH.: Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions.J Cutan Pathol,20: 229–236, 1993.
8.
WoosleyJ.T., DietrichD.R.: Prognostic significance of PCNA grade in malignant melanoma.J Cutan Pathol,20: 498–503, 1993.
9.
Klein-ParkerH.A., WarshawskiL., TronV.A.: Melanocytes in human skin express Bcl-2 protein.J Cutan Pathol,21: 297–301, 1994.
10.
CollinsK.A., WhiteW.L.: Intercellular adhesion molecule 1 (ICAM-1) and Bcl-2 are differentially expressed in early evolving malignant melanoma.Am J Dermatopathol,17: 429–438, 1995.
11.
HockenberryD., NunezG., MillmanC., SchreiberR.D., KorsmeyerS.J.: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.Nature,348: 334–336, 1990.
12.
CianfrigliaM., WillinghamM., TombesiM., ScagliottiG.V., FrascaG.: P-glycoprotein epitope mapping I. Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM 4.17 murine monoclonal antibody to human multidrug-resistant cells.Int J Cancer,56: 153–160, 1994.
13.
GoldsteinL.G., GalaskiH., FojoA., LaiS.L., GazdarA., PirkerR., GreenA., CristW., BroduerG.M., LiebarM., CossmanJ., GottesmanM.M., PastanI.: Expression of a multidrug-resistance gene in human cancers.J Natl Cancer Inst,81: 116–124, 1989.
14.
GottesmanM.M., PastanI.: Resistance to multiple chemotherapeutic agents in human cancer cells.Trends Pharmacol Sci,9: 54–58, 1988.
15.
PetersW.H.M., WobbesT., RoelofsH.M.J., JansenJBMJ: Glutathione, glutathione S-transferase and P170 glycoprotein in metastases of malignant melanomas.Int J Oncol,4: 1323–1327, 1994.
16.
Cordon-CardoC., O'BrienJ.P., BocciaJ.: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumour tissues.J Histochem Cytochem,38: 1277–1287, 1990.
17.
YoonS-S, FidlerI.J., BeltranP.J., BucanaC.D., WangY.F., FanD.: Intratumoral heterogeneity for and epigenetic modulation of mdr-1 expression in murine melanoma.Melanoma Research,7: 275–287, 1997.
18.
MolinariA., CalcabriniA., MeschiniS., StringaroA., Del BufaloP., CianfrigliaM., AranciaG.: Detection of P-glycoprotein in the, Golgi apparatus of drug untreated human melanoma cells.Int J Cancer,75: 885–893, 1998.
19.
CristofoliniM., BoiS., GirlandoS., ZumianiG., CristofoliniP., Dalla PalmaP., DoglioniC., BarbareschiM.: p53 protein expression in nevi and melanomas.Arch Dermatol,129: 739–743, 1993.
20.
YamamotoM., TakahashiH., SaitohK., HorikoshiT., TakahashiM.: Expression of the p53 protein in malignant melanomas as a prognostic indicator.Arch Dermatol Res,287: 146–151, 1995.
21.
BjornhagenV., BonfocoE., Mansson BrahmeE., LindholmJ., AuerG.: Morphometric, DNA and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.Am J Dermatopathol,16: 615–623, 1994.
22.
TakahashiH., StruttonG.M., ParsonsG.P.: Determination of proliferating fractions in malignant melanomas by anti-PC-NA/cyclin monoclonal antibody.Histopathology,18: 221–227, 1991.
23.
TuP., MiyauchiS., MikíY.: Proliferative activities in Spitz nevus compared with melanocytic nevus and malignant melanoma using expression of PCNA/cyclin and mitotic rate.Am J Dermatopathol,15: 311–314, 1993.
24.
TokudaY., MukaiK., MatsunoY., FuruyaS., ShimosatoY., TakasakiY., SaidaT., IshiharaK.: Proliferative activity of cutaneous melanocytic neoplasms defined by a proliferating cell nuclear antigen labelling index.Arch Dermatol Res,284: 319–323, 1992.
25.
CerroniL., SoyerH.P., KerlH.: Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi.Am J Dermatopathol,17: 7–11, 1995.
26.
Saenz-SantamariaM.C., ReedJ.A., Mc NuttS., SheaC.R.: Immunohistochemical expression of Bcl-2 in melanomas and intradermal nevi.J Cutan Pathol,21: 393–397, 1994.
27.
TronV.A., KrajewskiS., Klein-ParkerH., LiG., HoV.C., ReedJ.C.: Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.Am J Pathol,146: 643–650, 1995.
28.
SchadendorfD., HerfordtR., CzarnetzkiB.M.: P-glycoprotein expression in primary and metastatic malignant melanoma.Br J Dermatol,132: 551–555, 1995.
29.
FuchsB., OstmeierH., SuterL.: P-glycoprotein expression in malignant melanoma.Cancer Res Clin Oncol,117: 168–171, 1991.
30.
BergerW., ElblingL., Minai-PourM., VetterleinM., PirkerR., KokoschkaE.M., MickscheM.: Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines.Int J Cancer,59: 717–723, 1994.
